|
The field of sleep pharmacology is dynamic in nature and rapid advances are occurring in the field.
For example, screening for new drug candidates, development of new drugs, identification of molecular targets, and works related to its efficacy and safety profiles. Furthermore, this leads to the development of evidence-based therapeutic guidelines.
Insomnia Disorder: Epidemiology, Causes, and Pharmacotherapy consolidates the latest developments into one volume. It provides the latest, up-to-date knowledge regarding sleep and sleep therapeutics for sleep physicians, sleep researchers, psychiatrists, and any medical professional interested in the interdisciplinary areas of sleep therapeutics. Chapters include topics such as neurobiology, neurotransmitters, regulation of sleep and wakefulness, and overview of all current pharmacotherapies for insomnia.
Table of Contents
1. Neurobiology of sleep and waking
2. Neurotransmitters and sleep
3. Regulation of sleep and wakefulness (two-process model of sleep and three-process model of alertness)
3. Chronobiotics and chronohypnotics
4. Normal sleep in children adolescents, adults, and older adults
5. Insomnia: Overview and classification
6. Insomnia characteristics in children, adolescents, adults, and older adults
7. Mechanism of action of presently available hypnotic drugs
8. Pharmacokinetics of presently available hypnotic drugs
9. Non-pharmacological treatment of an insomnia disorder
10. Benzodiazepine hypnotics
11. “Zeta drugs”: Zopiclone, Eszopiclone, Zolpidem, and Zaleplon
12. Melatonin and melatonin receptor agonists (Ramelteon, Tasimelteon)
13. Histamine H1 receptor antagonists (with special emphasis on low-dose Doxepin)
14. Orexin receptor antagonists (Suvorexant, Lemborexant)
15. Insomnia and CAM therapies: an evidence-based approach
|
